# Remimazolam on the Incidence of Postoperative Acute Kidney Injury

> **NCT07674719** · NA · NOT_YET_RECRUITING · sponsor: **Seoul National University Bundang Hospital** · enrollment: 78 (estimated)

## Conditions studied

- Remimazolam
- Propofol
- Acute Kidney Injury
- Hemodynamic Stability
- Hepatobiliary Surgery
- Fluid Therapy
- Fluid Therapy DURING SURGERY

## Interventions

- **DRUG:** Remimazolam (Byfavo)
- **DRUG:** propofol

## Key facts

- **NCT ID:** NCT07674719
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-26
- **Primary completion:** 2027-06-26
- **Final completion:** 2028-06-26
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674719, "Remimazolam on the Incidence of Postoperative Acute Kidney Injury". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07674719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*